Article Text

This article has a correction. Please see:

other Versions

Download PDFPDF
Extended report
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
  1. Edward Keystone1,
  2. Mark C Genovese2,
  3. Lars Klareskog3,
  4. Elizabeth C Hsia4,5,
  5. Stephen Hall6,
  6. Pedro C Miranda7,
  7. Jacek Pazdur8,
  8. Sang-Cheol Bae9,
  9. William Palmer10,
  10. Stephen Xu4,
  11. Mahboob U Rahman4,5
  1. 1University of Toronto and Mount Sinai Hospital, Toronto, Ontario, Canada
  2. 2Stanford University, Palo Alto, California, USA
  3. 3Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
  4. 4Centocor Research and Development, Inc, Malvern, Pennsylvania, USA
  5. 5University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
  6. 6Cabrini Medical Centre, Malvern, Victoria, Australia
  7. 7Universidad de Chile and Hospital San Juan de Dios, Santiago, Chile
  8. 8Instytut Reumatologii, Warszawa, Poland
  9. 9Department of Rheumatology, The Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea
  10. 10Westroads Medical Group, Omaha, Nebraska, USA
  1. Correspondence to Dr Edward Keystone, University of Toronto and Mount Sinai Hospital, 60 Murray Street, 2nd Floor, Room 2-006, Toronto, Ontario M5G 1X5, Canada; edkeystone{at}


Objective To evaluate the efficacy and safety of golimumab to 52 weeks in patients with active rheumatoid arthritis despite methotrexate.

Methods Patients were randomly assigned to receive placebo plus methotrexate (group 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg plus methotrexate (group 3) and golimumab 100 mg plus methotrexate (group 4). At week 16, patients in groups 1, 2 and 3 who had less than 20% improvement in tender and swollen joints entered early escape. At week 24, patients in group 1 who had not entered early escape crossed over to 50 mg golimumab plus methotrexate.

Results At week 16, 31%, 27% and 17% of patients in groups 1, 2 and 3, respectively, entered early escape. At week 52, 44%, 45%, 64% and 58% of patients in groups 1, 2, 3 and 4, respectively, achieved 20% improvement in the American College of Rheumatology criteria; and 34%, 31%, 42% and 53%, respectively, achieved low disease activity (≤3.2) according to the 28-joint disease activity score. Patients in group 4 appeared to have an increased risk of serious adverse events and serious infections.

Conclusion The results of various outcome measures showed that the response rates achieved by patients receiving golimumab to 24 weeks were sustained to 52 weeks. The safety profile appeared to be consistent with the known safety profile of tumour necrosis factor inhibitors.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This study was funded by Centocor Research and Development, Inc, a wholly owned subsidiary of Johnson & Johnson, Inc and Schering Plough Research Institute, Inc.

  • Competing interests EK, MCG, LK, SH, PCM, JP, S-CB and WP (or their institutions) have received research grants from Centocor and/or Schering-Plough. LK and EK have received consulting fees from Centocor and/or Schering-Plough. ECH, MUR and SX are employees of Centocor Research and Development, Inc and own stock and/or stock options in Johnson & Johnson, Inc.

  • Ethics approval This study protocol was conducted with the approval of the ethics committee at each study site.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles

  • Miscellaneous
    BMJ Publishing Group Ltd and European League Against Rheumatism